أرسل هذا في رسالة قصيرة: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

  ______     ___      ______    _____     _____   
 /_   _//   / _ \\   /_   _//  |  ___||  /  ___|| 
   | ||    | / \ ||    | ||    | ||__   | // __   
  _| ||    | \_/ ||   _| ||    | ||__   | \\_\ || 
 /__//      \___//   /__//     |_____||  \____//  
 `--`       `---`    `--`      `-----`    `---`